Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders

BACKGROUND: The goal of this observational, open-label, cohort study was to determine whether prophylactic migraine treatment with galcanezumab, a peripherally acting drug, alters the incidence of premonitory symptoms, and/or occurrence of headache after exposure to triggers or aura episodes in trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashina, Sait, Melo-Carrillo, Agustin, Toluwanimi, Ajayi, Bolo, Nicolas, Szabo, Edina, Borsook, David, Burstein, Rami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018924/
https://www.ncbi.nlm.nih.gov/pubmed/36927366
http://dx.doi.org/10.1186/s10194-023-01560-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018924/
https://www.ncbi.nlm.nih.gov/pubmed/36927366
http://dx.doi.org/10.1186/s10194-023-01560-x

Ejemplares similares